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PHOTOINITIATING POLYMERISABLE 
COMPOSITION 
[ 0001 ] The present invention relates to an injectable com 
position . An in vivo method of forming a polymeric struc 
ture , such as a medical device , is also described . There is 
also provided a method of medical treatment including the 
implantation of the composition to a human or animal body , 
and the subsequent polymerization of the composition 
within the human or animal body . 
BACKGROUND TO THE INVENTION 
[ 0002 ] It is known to use multi - photon photo - polymeriza 
tion ex vivo to build a structure modelled on a biological 
organ ( for example see US2013197668A1 ) . A solid block of 
gel containing monomers and a 2 - photon active photo 
initiator is prepared as a raw material . The shape of a desired 
object is traced out by the control of laser beams , optionally 
there may be additional steps such as a fixing step , and then 
excess gel is washed away to leave the desired structure . 
[ 0003 ] In one type of photo - polymerization , light is 
absorbed directly by a reactant monomer . In a second type 
of photo - polymerization , light is absorbed by a photo 
initiator material which absorbs the light and then transfers 
energy to the monomer to effect polymerization . 
[ 0004 ] It is known to use multi - photon techniques destruc 
tively to induce controlled release of drugs from a structure 
in vivo ( see for example US2003191458A1 ) . 
10005 ] Currently the provision of structures in vivo 
requires incision and implantation . The present invention is 
advantageous because it permits in situ in vivo fabrication of 
structures and may require as few as one implantation ( suitably one injection ) of the precursor materials . 
animal body wherein the composition comprises a polymeri 
sable precursor and a photo - initiator wherein the photo 
initiator causes the polymerisable precursor to polymerise 
where the photo - initiator is in its excited state ; 
10013 ] illuminating the site with electromagnetic radiation 
having a wavelength of 400 to 1600 nm , wherein absorption 
of two or more photons of the electromagnetic radiation 
excites the photo - initiator causing initiation of polymerisa 
tion of the polymerisable precursor to form a polymer within 
the human or animal body , wherein the polymer is visible on 
the exterior of the human or animal body . 
[ 0014 ] Generally , the visual marking is in the form of a 
tattoo . 
10015 ] According to one embodiment , the composition 
includes second photo - initiatable functional moieties which 
become excited at a different wavelength to the photo 
initiator and wherein the polymer may be dis - assembled 
through illumination of the site with electromagnetic radia 
tion having a second wavelength . The second wavelength 
may be at least 200 nm higher or lower than the first 
wavelength wherein absorption of two or more photons of 
the electromagnetic radiation causes the second photo - ini 
tiatable functional moieties on the polymer to become 
excited and destroy the polymer . 
[ 0016 ] According to an aspect of the present invention , 
there is provided an injectable composition comprising a 
polymerisable precursor and a photo - initiator wherein the 
photo - initiator causes the polymerisable precursor to 
polymerise where the photo - initiator is in its excited state , 
[ 0017 ] wherein absorption of two or more photons of 
electromagnetic radiation having a wavelength of 400 
to 1600 nm excites the photo - initiator causing initiation 
of polymerisation of the polymerisable precursor , 
[ 0018 ] wherein the resultant polymer has an associated 
electrical conductivity of at least 10 - 10 S / cm to 104 
S / cm or more . 
[ 0019 ] According to a further aspect of the present inven 
tion , there is provided a buffered aqueous based composition 
comprising monomers that are derivatives of pyrrole , ani 
line , thiophene , 3 , 4 - ethylenedioxythiophene , fluorene , phe 
nylene , pyrene , azulene , napthalene , indole , azepine , p - phe 
nylene sulfide , p - phenylene vinylene , and / or furans ; and 
moreover , a photo - initiator , and dye ( s ) . 
[ 0020 ] According to a further aspect of the present inven 
tion there is provided a buffered aqueous based composition 
comprising pyrrole , a photo - initiator ( generally irgacure ) 
and a dye . 
[ 0021 ] According to a further aspect of the present inven 
tion there is provided a method of forming a polymeric 
structure within a human or animal body utilising the 
methods as described herein . 
[ 0022 ] According to a further aspect of the present inven 
tion , there is provided a composition as described herein for 
use in therapy . 
[ 0023 ] . According to a further aspect of the present inven 
tion , there is provided a composition as described herein for 
use in the treatment of conditions that respond to electricity 
( i . e . using the polymer deposited as an electrode to stimulate 
the tissue surrounding it for deep brain stimulation , for 
electrical stimulation of neurons , stem cells or muscle cells ) , 
or prevention of cell migration cancer cells , bacteria , etc ) , 
or the delivery of active ingredients ( drugs ) entrapped within 
the polymer matrix . 
STATEMENT OF INVENTION 
[ 0006 ] A method of forming a polymer within a human or 
animal body comprising : 
[ 0007 ] implanting a composition at a site in the human 
or animal body wherein the composition comprises a 
polymerisable precursor and a photo - initiator wherein 
the photo - initiator causes the polymerisable precursor 
to polymerise where the photo - initiator is in its excited 
state ; [ 0008 ] illuminating the site with electromagnetic radia 
tion having a first wavelength of 400 to 1600 nm , 
wherein absorption of two or more photons of the 
electromagnetic radiation excites the photo - initiator 
causing initiation of polymerisation of the polymeris 
able precursor to form a polymer within the human or 
animal body , wherein polymerisation causes a change 
in physical state of the polymerisable precursor ; 
[ 0009 ] wherein the polymer has an electrical conduc 
tivity of 10 - 10 S / cm to 104 S / cm or more . [ 0010 ] Generally , the change in physical state involves 
solidification of the polymerisable precursor . Alternatively , 
the viscosity of the polymerisable precursor may be greatly 
increased , for example to yield a gel ( including a hydrogel ) , 
paste , foam or plastic . 
[ 0011 ] According to a further aspect of the present inven 
tion , there is provided a method of producing a visual 
marking on the exterior of a human or animal body com 
prising : 
[ 0012 ] implanting a composition at a site in the human or 
animal body 1 cm or less from the exterior of the human or 
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[ 0024 ] There is also provided a method of medical treat - 
ment comprising forming a polymer within a human or 
animal body in accordance with the method described 
herein . 
[ 0025 ] In yet another aspect , the present teachings include 
a kit , where the kit includes one or more of the compositions 
of the present teachings , or the components necessary to 
form the compositions of the present invention , and instruc 
tions for use thereof . Generally , the kit would comprise an 
energy source . 
[ 0026 ] According to a further embodiment , there is pro 
vided a system for performing the methods disclosed herein . 
The system can include the composition as disclosed herein 
and one or more energy sources , typically lasers . The system 
may include an analytical instrument used to measure the 
wavelength and intensity of the energy source ( s ) , and / or to 
measure the amount of composition implanted in the human 
or animal body . The system also can include a suitably 
programmed computer for carrying out one or more steps of 
the methods . For example , the suitably programmed com 
puter can carry out or assist in one or more of control of the 
intensity of the energy source ( s ) , measuring any fluctuations 
in the intensity of the energy source ( s ) , and equivalents 
thereof . [ 0027 ] Throughout the Application , where compositions 
are described as having , including , or comprising specific 
components , or where processes are described as having , 
including , or comprising specific process steps , it is con 
templated that compositions of the present teachings also 
consist essentially of , or consist of , the recited components , 
and that the processes of the present teachings also consist 
essentially of , or consist of , the recited process steps . 
[ 0028 ] In the Application , where an element or component 
is said to be included in and / or selected from a list of recited 
elements or components , it should be understood that the 
element or component can be any one of the recited elements 
or components , or the element or component can be selected 
from a group consisting of two or more of the recited 
elements or components . Further , it should be understood 
that elements and / or features of a composition , an apparatus , 
or a method described herein can be combined in a variety 
of ways without departing from the spirit and scope of the 
present teachings , whether explicit or implicit herein . 
[ 0029 ] The use of the terms include , ” “ includes ” , 
" including , " " have , " " has , ” or “ having ” should be generally 
understood as open - ended and non - limiting unless specifi 
cally stated otherwise . 
[ 0030 ] The use of the singular herein includes the plural 
( and vice versa ) unless specifically stated otherwise . In 
addition , where the use of the term " about ” is before a 
quantitative value , the present teachings also include the 
specific quantitative value itself , unless specifically stated 
otherwise . As used herein , the term “ about ” refers to a + 10 % 
variation from the nominal value unless otherwise indicated 
or inferred . 
[ 0031 ] It should be understood that the order of steps or 
order for performing certain actions is immaterial so long as 
the present teachings remain operable . Moreover , two or 
more steps or actions may be conducted simultaneously . 
[ 0032 ] As used herein , “ pharmaceutically acceptable ” 
refers to a substance that is acceptable for use in pharma 
ceutical applications from a toxicological perspective and 
does not adversely interact with the active ingredient . 
Accordingly , pharmaceutically acceptable carriers are those 
that are compatible with the other ingredients in the formu 
lation and are biologically acceptable . Supplementary active 
ingredients can also be incorporated into the pharmaceutical 
compositions . 
[ 0033 ] Compounds and therapeutic combinations of the 
present teachings can be useful for treating a pathological 
condition or disorder in a patient , for example , a human . As 
used herein , “ treating ” refers to partially or completely 
alleviating and / or ameliorating the condition and / or symp 
toms thereof . The present teachings accordingly include a 
method of providing to a patient a pharmaceutical compo 
sition that includes a compound or therapeutic combination 
of the present teachings in combination or association with 
a pharmaceutically acceptable carrier . Compounds and 
therapeutic combinations of the present teachings can be 
administered alone or in combination with other therapeu 
tically effective compounds or therapies for the treatment of 
a pathological condition or disorder . 
[ 0034 ] As used herein , " patient ” refers to a human , ani 
mal , fish or bird , in particular a mammal , such as a human 
although mention may also be made of primates , dogs , cats , 
rats , horses , camels , farm livestock such as cattle sheep , 
pigs , goats , deer ; birds including chicken , geese , birds of 
prey and endangered animals including endangered birds . 
[ 0035 ] Because the present teachings provide pharmaceu 
tical formulations and their intended use is with patients 
such as humans , each of the ingredients or compounds of a 
pharmaceutical formulation described herein can be a phar 
maceutically acceptable ingredient or compound . 
[ 0036 ] As used herein , a “ compound ” refers to the com 
pound itself and its pharmaceutically acceptable salts and 
hydrates unless otherwise understood from the context of the 
description or expressly limited to one particular form of the 
compound , i . e . , the compound itself , or a pharmaceutically 
acceptable salt or hydrate thereof . 
[ 0037 ] Features , integers , characteristics , described in 
conjunction with a particular aspect , embodiment or 
example of the invention are to be understood to be appli 
cable to any other aspect , embodiment or example described 
herein unless incompatible therewith . 
DETAILED DESCRIPTION 
[ 0038 ] Method 
[ 0039 ] A method of forming a polymer within a human or 
animal body comprising : 
[ 0040 ] implanting a composition at a site in the human 
or animal body wherein the composition comprises a 
polymerisable precursor and a photo - initiator wherein 
the photo - initiator causes the polymerisable precursor 
to polymerise where the photo - initiator is in its excited 
state ; [ 0041 ] illuminating the site with electromagnetic radia 
tion having a first wavelength of 400 to 1600 nm , 
wherein absorption of two or more photons of the 
electromagnetic radiation excites the photo - initiator 
causing initiation of polymerisation of the polymeris 
able precursor to form a polymer within the human or 
animal body , wherein polymerisation causes a change 
in physical state of the polymerisable precursor ; 
[ 0042 ] wherein the polymer has an electrical conduc 
tivity of 10 - 10 S / cm to 104 S / cm or more . 
[ 0043 ] Generally , the change in physical state involves 
solidification of the polymerisable precursor . Alternatively , 
the viscosity of the polymerisable precursor may be greatly 
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uy . 
increased , for example to yield a gel ( including a hydrogel ) , 
paste , foam or plastic . Advantageously , the polymerisation 
causes solidification of the polymerisable precursor . ( 0044 ) Generally , the dimensions of the polymerised area 
( in general the solidified area ) are at least 1 nm , typically at 
least 100 nm . Typically , the polymerised area has an asso 
ciated thickness of less than 1 cm . 
10045 ] Currently the provision of structures in vivo 
requires incision and implantation . The present invention is 
advantageous because it permits in situ in vivo fabrication of 
structures and may require as few as one injection of the 
precursor materials . 
[ 0046 ] The use of multi - photon technology is advanta 
geous because it may be controlled so that a desired pho 
tochemical reaction occurs only at the point of intersection 
of two or more photon beams . For example two - photon 
polymerisation may provide point by point scanning to build 
a desired structure . [ 0047 ] According to one aspect of the present invention , at 
least one of the beams may be scanned so as to produce a 
pattern . [ 0048 ] The composition is generally implanted through 
injection . The composition may be injected into the lower 
layers of the skin , or subcutaneously . The composition may 
be implanted via bolus injection . Alternatively , the compo 
sition may be implanted through the use of a catheter . 
[ 0049 ] Generally the composition is implanted 10 cm or 
less from the surface of the human or animal body , typically 
5 cm or less , suitably 1 cm or less , more suitably within 5 
mm of the surface of the human or animal bod . 
[ 0050 ] According to one embodiment , the composition is 
implanted to the lower layers of skin , or directly under the 
skin of the human or animal body . Alternatively , the com 
position may be implanted directly under the surface of the 
eye of the human or animal . Suitably the composition may 
be injected into other tissue , for example muscle or fat , or 
around an organ of the human or animal body . [ 0051 ] Alternatively , the composition may be implanted 
further from the surface of the human or animal body . The 
electromagnetic radiation source may be inserted into the 
body to illuminate the site of the implanted composition ( suitably through keyhole surgery ) . 
[ 0052 ] The closer the site of the implanted composition to 
the energy source upon illumination of the site by the energy 
source , the more targeted and controllable the polymerisa 
tion of the composition . [ 0053 ] Generally , the site of the implanted composition 
should be no more than 30 cm from the energy source upon 
illumination of the site , suitably 10 cm or less from the 
energy source . Typically the site is 5 cm or less from the 
energy source upon illumination , suitably 1 cm or less from 
the energy source upon illumination . 
10054 ] To excite the photo - initiator , a threshold amount of 
radiation must be absorbed . The wavelength of the incident 
radiation is generally 400 to 1600 nm . 
[ 0055 ] The threshold incident radiation is generally in the 
form of at least two photons from intersecting photon beams . [ 0056 ] Generally , the composition is subjected to electro 
magnetic radiation from outside the human or animal body 
to initiate polymerisation of the monomer . 
[ 0057 ] Absorption by the photo - initiator of a threshold 
amount of electromagnetic radiation excites the photo - ini 
tiator , and the excited photo - initiator initiates polymerisa 
tion of the polymerisable precursor . Generally , absorption of 
electromagnetic radiation from the intersection of two or 
more photon beams is required to excite the photo - initiator , 
meaning that the photochemical reaction is very controllable 
and predictable . 
[ 0058 ] The use of multi - photon technology is advanta 
geous because it may be controlled so that a desired pho 
tochemical reaction occurs only at the point of intersection 
of two or more photon beams . For example , two - photon 
polymerisation may provide point by point scanning to build 
a desired structure . 
[ 0059 ] Upon polymerisation , the polymerisable precursor 
undergoes a change in physical state . Generally the 
polymerisable precursor solidifies . Alternatively , a hydrogel 
or plastics material may be formed . Generally , the area of 
polymerisation , of the precursor is within 1 , 000 , 000 nm of 
the incident threshold electromagnetic radiation , typically 
within 10 , 000 nm of the intersection of two or more photon 
beams . 
[ 0060 ] The electromagnetic radiation is generally emitted 
by an energy source such as a laser . 
[ 0061 ] The dimensions of the polymer formed according 
to the method of the present invention ( width , length , 
thickness ) are generally at least 10 nm , typically 10 nm to 10 
cm , suitably 50 nm to 5 cm thick , more suitably 50 nm to 1 
cm , advantageously 50 nm to 100 nm . 
[ 0062 ] Generally , the polymer formed is a relatively thin 
polymer film or coating , and has a relatively large associated 
length and width . The polymer generally has a thickness of 
10 nm to 200 nm , ( typically a maximum thickness of 100 
nm ) and a width and / or length of 1 cm to 5 cm . 
[ 0063 ] According to one embodiment , the polymer formed 
according to the method of the present invention ( width , 
length , thickness ) may have dimensions of from 1 nm to 2 
mm . 
[ 0064 ] It is envisaged that the polymer may have dimen 
sions of from 10 cm to 2 m . 
[ 0065 ] Where the polymer has a thickness of more than 1 
cm , areas of the composition furthest from an external 
surface of the human or animal body are generally polymer 
ised before areas of the composition closer to an external 
surface of the human or animal body by controlling the 
intersection of the photon beams within the human or animal body . 
[ 0066 ] In order to allow adequate control , any area of the 
composition to be polymerised is generally no more than 10 
cm from an external surface of the human or animal body . 
Alternatively , the energy source may be inserted into the 
human or animal body to allow polymerisation of compo 
sitions at greater depths . 
[ 0067 ] The composition may suitably include a visual 
marker such as a dye to assist medical practitioners such as 
surgeons as they are forming the polymer . The dye could 
become apparent as the polymerisable precursor polymer 
ised , or may be visible in the polymerisable precursor but 
not in the polymer . 
[ 0068 ] The polymer formed according to the method of 
the present invention may be in the form of a polymeric 
structure or medical device . According to one embodiment , 
cells from the human or animal body may colonise the 
polymeric structure formed over time . 
[ 0069 ] The polymer formed has an electrical conductivity 
of at least 10 - 1° S / cm to 104S / cm , generally 1 S / cm to 5 , 000 
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S / cm , suitably 10 S / cm to 1 , 000 S / cm , and this allows 
potential uses in the fabrication of devices within the human 
or animal body . 
10070 ) Particular mention may be made of the use of a 
polymer formed in vivo in accordance with the method of 
the present invention in the formation of an electrode 
( including an electrode with a connection to an implanted 
device / chip ) , an antenna , an induction loop with connections 
to power an implanted device wirelessly , an electro - mag 
netic shield , a support structure , a radio , a hearing aid , ID tag 
or tattoo . 
[ 0071 ] According to one embodiment , the polymer formed 
may be a stimulus responsive material . The physical dimen 
sions of the polymer may alter in response to a stimulus , in 
particular the shape / size / properties ( for instance mechanics , 
optical , electrical properties ) may alter in response to the 
stimulus . The polymer may deliver drugs / cells in response to 
the stimulus 
[ 0072 ] Method of Producing a Visual Marking 
[ 0073 ] According to a further aspect of the present inven 
tion , there is provided a method of producing a visual 
marking on the exterior of a human or animal body com 
prising : 
[ 0074 ) implanting a composition at a site in the human 
or animal body 1 cm or less from the exterior of the 
human or animal body wherein the composition com 
prises a polymerisable precursor and a photo - initiator 
wherein the photo - initiator causes the polymerisable 
precursor to polymerise where the photo - initiator is in 
its excited state ; [ 0075 ] illuminating the site with electromagnetic radia 
tion having a wavelength of 400 to 1600 nm , wherein 
absorption of two or more photons of the electromag 
netic radiation excites the photo - initiator causing ini 
tiation of polymerisation of the polymerisable precur 
sor to form a polymer within the human or animal body , 
wherein the polymer is visible on the exterior of the 
human or animal body . 
[ 0076 ] The resultant polymer generally has an electrical 
conductivity of 10 - 10 S / cm to 104 S / cm or more , suitably 
0 . 0001 S / cm to 1 , 000 S / cm ; typically , 0 . 001 S / cm to 1 S / cm . 
[ 0077 ] The resultant polymer is generally one colour , 
although functional groups may be added to alter the colour 
of the polymer at different areas . 
[ 0078 ] According to one embodiment , the resultant poly 
mer shows more than one colour on the exterior of the 
human or animal body . 
[ 0079 ] Generally , the visual marking is in the form of a 
tattoo . 
[ 0080 ] The composition is suitably injected into the lower 
surfaces of the skin of the human or animal body . The visual 
marking may grow out as the skin is shed . Alternatively , the 
composition may be injected just under the skin of the 
human or animal body , to provide a permanent visual 
marking . 
[ 0081 ] The visual marking may be altered or removed 
using the polymer dis - assembling methods of the present 
teachings . This can provide significant advantages over 
current tattooing methods . 
[ 0082 ] The visual marking of the present invention may 
provide an alternative to branding animals . The visual 
marking of the present teachings may be altered or removed 
using the polymer dis - assembling methods of the present 
teachings , and this can prove useful if the ownership of the 
animal changes . 
[ 0083 ] Method of Dis - Assembling Polymer 
[ 0084 ] By use of suitable chemistry in the present inven 
tion , a first multi - photon reaction ( using first functional 
moieties ) may be used to assemble a structure ; and a second 
multi - photon reaction at a different energy ( using second 
functional moieties ) may be used later to disassemble the 
same structure . 
[ 0085 ] According to one embodiment , the composition 
includes second photo - initiatable functional moieties which 
become excited at a different wavelength to the photo 
initiator . Generally the difference in wavelength is at least 
200 nm . The polymerisable precursor generally includes the 
second photo - initiatable functional moieties , and following 
polymerisation thereof , the polymer generally comprises the 
second photo - initiatable functional moieties . [ 0086 ] The polymer formed according to the method of 
the present teachings may be dis - assembled through illumi 
nation of the site with electromagnetic radiation having a 
second wavelength . The second wavelength may be at least 
200 nm higher or lower than the first wavelength wherein 
absorption of two or more photons of the electromagnetic 
radiation causes the second photo - initiatable functional moi 
eties on the polymer to become excited and destroy the 
polymer . 
[ 0087 ] The method described herein may include dis 
assembling the polymer formed by illuminating the site with 
electromagnetic radiation having a second wavelength . The 
second wavelength may be different to the first wavelength 
by at least 200 nm , wherein absorption of two or more 
photons of the electromagnetic radiation excites second 
photo - initiatable functional moieties on the polymer , and the 
excited second photo - initiatable functional moieties destroy 
the polymer . 
[ 0088 ] As for the method of forming the polymer , the 
photo - initiatable destruction is precisely targeted and con 
trollable . Generally , the destruction of the polymer is limited 
to 5 mm or less , typically 1 mm or less from the location of 
the incident electromagnetic radiation ; typically , from the 
location of the intersection of two or more photon beams . [ 0089 ] Upon destruction of the polymer through the reac 
tion initiated through the excitation of the second photo 
initiatable functional moieties , waste products are formed 
and these are generally non - toxic to the human or animal 
body . Generally , the waste products are bio - absorbable and 
may be absorbed by the human or animal body . 
10090 ) Suitable photo - initiatable functional moieties to 
destroy the polymer include : azobenzene ( excitable at 
around 366 to 420 nm ) , o - nitrobenzyl ( excitable at 350 , 750 
nm ) , 3 , 4 - dihydroxycinnamic acid - co - 4 - hydroxycinnamic 
acid ( P ( 3 , 4DHCA - CO - 4HCA ) ) ( at 254 , 280 nm ) , dipalmi 
toylphosphatidylcholine ( at 514 nm ) , diazonaphthoquinone 
based molecules ( using UV / NIR ) . 
[ 0091 ] Generally , the second photo - initiatable functional 
moieties are initiated at lower wavelengths compared to the 
wavelength for exciting the photo - initiator . 
[ 0092 ] Composition 
[ 0093 ] According to an aspect of the present invention , 
there is provided an injectable composition comprising a 
polymerisable precursor and a photo - initiator wherein the 
photo - initiator causes the polymerisable precursor to 
polymerise where the photo - initiator is in its excited state , 
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[ 0094 ] wherein absorption of two or more photons of 
electromagnetic radiation having a wavelength of 400 
nm to 1600 nm excites the photo - initiator causing 
initiation of polymerisation of the polymerisable pre 
cursor , 
[ 0095 ] wherein the resultant polymer has an associated 
electrical conductivity of at least 10 - 10 S / cm to 104 
S / cm or more . [ 0096 ] The composition generally includes a visual indi 
cator which alters upon polymerisation of the polymerisable 
precursor . Suitable visual indicators include dyes . Generally , 
the visual indicator is visible in the polymerisable precursor 
but not in the polymer . Alternatively , the visual indicator 
may be visible in the polymer but not the polymerisable 
precursor . 
[ 0097 ) The visual indicator may be visible upon illumi 
nation with UV light . 
[ 0098 ] The visual indicator may change colour between 
monomer and polymer . 
[ 0099 ] The incorporation of a visual indicator which alters 
upon polymerisation of the polymerisable precursor is useful 
following implantation of the composition into a human or 
animal body . Specifically , it can assist in showing the precise 
location of the composition . 
[ 0100 ] Generally said composition has a viscosity in the 
range from 1 centipoise ( similar to water ) , to 250 , 000 
centipoise ( similar to peanut butter ) . A viscosity of 1 cen 
tipoise or more helps to ensure the injected composition is 
retained in a predictable position ( generally at the site of 
injection ) . A viscosity of 250 , 000 centipoise or less reduces 
the risk of blockages within the human or animal body , 
which can be of paramount importance where the compo 
sition is implanted near a blood vessel . 
[ 0101 ] Typically , the composition is buffered to a pH of 
4 - 10 , but most commonly pH 7 . 4 . Generally , the composi 
tion is sterilised prior to implantation . [ 0102 ] The polymerisable precursor may comprise , con 
sist or consist essentially of monomers having at least one 
olefinic bond , oligomers having at least one olefinic bond , 
polymers having at least one olefinic bond , olefins , haloge 
nated olefins , acrylates , methacrylates , pyrroles , acrylam 
ides , bisacrylamides , styrenes , epoxides , cyclohexeneoxide , 
amino acids , peptides , proteins , fatty acids , lipids , nucleo 
tides , oligonucleotides , synthetic nucleotide analogues , 
nucleic acids , sugars , carbohydrates , cytokines , hormones , 
receptors , growth factors , drugs , and mixtures thereof . [ 0103 ] The composition generally comprises 5 - 50 wt . % 
polymerisable precursor . 
[ 0104 ] Generally , the polymer is an intrinsically conduc 
tive polymer . The polymer generally includes repeating 
units comprising at least one aromatic cycle , typically a 5 to 
7 member aromatic cycle , optionally including one or more 
heteroatoms , in particular one or more N or S heteroatoms . 
The repeating units may include one or more N , S or O 
atoms outside the aromatic cycle . [ 0105 ] The polymer generally includes repeating units 
comprising at least one double bond . 
[ 0106 ] Typically the polymer includes repeating units 
comprising more than one aromatic cycle , repeating units 
comprising an aromatic cycle and a double bond or repeat 
ing units comprising an aromatic cycle and one or more N , 
S or O atoms outside the aromatic cycle . [ 0107 ] Suitably the polymer comprises , consists or con 
sists essentially of one or more of the group consisting of 
poly ( fluorene ) s , polyanilines , polyphenylenes , polypyrenes , 
polyazulenes , polynaphthalenes , Poly ( acetylene ) s , Poly ( p 
phenylene vinylene ) , poly ( pyrrole ) s , polycarbazoles , poly 
indoles , polyazepines , poly ( thiophene ) s , poly ( 3 , 4 - ethylene 
dioxythiophene ) , poly ( p - phenylene sulfide ) , polpyrenes , 
polyfurans . 
[ 0108 ] Alternatively , the polymer may be a block copo 
lymer with conductive blocks , hyperbranched polymers , 
dendrimers , supramolecular polymers , where the conductive 
blocks are derivatives of derivatives of pyrrole , aniline , 
thiophene , 3 , 4 - ethylenedioxythiophene , fluorene , phe 
nylene , pyrene , azulene , napthalene , indole , azepine , p - phe 
nylene sulfide , p - phenylene vinylene , and / or furans . [ 0109 ] According to one embodiment , the polymer may 
comprise , consist of or essentially consist of fullerenes , for 
example bucky - balls , nanotubes and nano - horns or gra 
phenes . 
[ 0110 ] The polymer is biocompatible . [ 0111 ] Generally the polymer itself has a relatively high 
associated conductivity ( 10 - 10 S / cm to 104 S / cm ) . [ 0112 ] Alternatively , the composition may include a 
polymerisable precursor suitable to form a polymer having 
a relatively low electrical conductivity such as ceramics or 
glasses and an electrically conductive material dispersed 
throughout . Suitable such conductive material includes inor 
ganic metals and alloys such as Au , Ti , Steel , CoCr , 
CoCrMo , TigAl V , TigAl , Nb , iron , WE43 magnesium alloy , 
Mg /Zn . 
[ 0113 ] The composition of the present teachings includes 
a polymerisable precursor and a photo - initiator . 
[ 0114 ] The polymerisable precursor itself may comprise 
the photo - initiator , in particular , the polymeric precursor 
may be functionalised with photoactivatable groups . 
[ 0115 ] Alternatively , or additionally , the photo - initiator 
may be provided separately from the polymerisable precur 
sor . [ 0116 ] According to one embodiment , the polymerisable 
precursor may be encapsulated within , or coated with the 
photo - initiator . 
[ 0117 ] Any suitable photo - initiator may be used . Mention 
may be made of azo compounds , azobisisobutyronitrile , 
peroxides , benzoyl peroxide , aliphatic ketones and dike 
tones , aromatic diketones , benzophenone , 9 - fluorenone 
2 - carboxylic acid , ion pairs , the ion pair Fe3OH® , the ion 
pair Pb2 + C1 ) , photosensitive dyes , eosin , rose Bengal , 
erydirosin , photosensitive transition metal derivatives , and 
Mn ( CO ) 10 in the presence of organic halides , triarylsulfo 
nium salts with complex metal halide anions , diaryliodo 
nium salts with complex metal halide anions , mixed arene 
cyclopentadienyl metal salts of complex metal halide 
anions , and ( 6 - benzene ) ( 5 - cyclopentadienyl ) Fe ( II ) 
hexafluorophosphate . 
[ 0118 ] The composition generally comprises 1 - 10 wt . % 
photo - initiator . 
[ 0119 ] . The composition generally includes second photo 
initiatable functional moieties which become excited at a 
different wavelength to the photo - initiator . Generally the 
difference in wavelength is at least 200 nm . 
10120 ) Other photo - initiation systems include , but are not 
limited to , redox - type photo - initiators useful in aqueous 
systems ( e . g . , ion pairs such as Fe® + OH® , and Pb2 + C1 _ ) , 
photosensitive dyes such as eosin , rose Bengal , and eryth 
rosin , and transition metal derivatives such as Mn , ( CO ) , in 
the presence of organic halides , riboflavin / triethanolamine , 
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Irgacure 184 , Irgacure 369 , Irgacure 651 , Irgacure 2959 , 
azobisisobutyronitrile , peroxides such as benzoyl peroxide , 
aliphatic carbonyl compounds such as ketones and dike 
tones , and aromatic diketones such as benzophenone and its 
derivatives , and 9 - fluorenone 2 - carboxylic acid . [ 0121 ] The polymerisable precursor may comprise the 
second photo - initiatable functional moieties . 
0122 ] Generally , the composition is aqueous , although in 
some embodiments non - aqueous compositions may be of 
utility . 
[ 0123 ] The composition is generally in the form of a gel , 
cream , liquid , suspension , solution , emulsion or foam . Typi 
cally , the composition is in the form of an injectable gel . 
Suitable gel based carriers include synthetic polymers ( e . g . 
polyethylene glycol ) and biopolymers ( e . g . polysaccharides 
[ hyaluronic acid , chitin , chitosan , alginate , cellulose ] , pro 
teins [ collagen , fibronectin , silk , etc . ) , lignins , polynucle 
otides , extracellular matrix ) . [ 0124 ] The composition may suitably comprise 5 - 25 % gel 
based carrier . [ 0125 ] According to one embodiment , the composition 
includes particles in an injectable carrier material , said 
particles comprising a core having an electrical conductivity 
of at least 10 - 10 S / cm to 104 S / cm , and a coating comprising 
the photo - initiator . [ 0126 ] The composition generally comprises polymeris 
able precursors suitable for forming a polymer having an 
electrical conductivity of at least 10 - 10 S / cm , a photo 
initiator and a dye . 
[ 0127 ] . According to a further aspect of the present inven 
tion , there is provided a buffered aqueous based composition 
comprising derivatives of pyrrole , aniline , thiophene , 3 , 4 
ethylenedioxythiophene , fluorene , phenylene , pyrene , azu 
lene , napthalene , indole , azepine , p - phenylene sulfide , 
p - phenylene vinylene , and / or furans , a photo - initiator , a dye . 
[ 0128 ] According to a further aspect of the present inven 
tion there is provided a buffered aqueous based composition 
comprising pyrrole , a photo - initiator ( generally irgacure ) 
and a dye . 
[ 0129 ] The present invention will now be described by 
way of example only , with reference to the accompanying 
Figures , in which : 
[ 0130 ] FIG . 1 provides a schematic representation of the 
manufacture of a subcutaneous structure according to the 
present invention . ( not to scale ) ; [ 0131 ] FIG . 2 provides a schematic representation of 
assembly and disassembly of polymers according to the 
present invention ; [ 0132 ] FIG . 3 is a halftone rendering of a photograph of a 
polymeric structure printed into vertebrate tissue . [ 0133 ] FIG . 1 shows schematically and not to scale the 
manufacture of a subcutaneous device according to the 
present invention . A first photon beam ( 101 ) and a second 
photon beam ( 103 ) pass from outside ( 105 ) tissue , through 
the surface ( 107 ) of tissue , into the interior of tissue ( 109 ) . 
Previously a region of precursor material ( 111 ) has been 
placed into the tissue ( 109 ) . The photon beams cause 
polymerisation of precursor monomers at the point of inter 
section ( 115 ) , and when the beams are moved , this point ( 115 ) moves and a polymerised structure ( 113 ) results . [ 0134 ] FIG . 2 shows schematically assembly and disas - 
sembly of polymers according to the present invention . Each 
square block ( 201 ) represents a monomer unit that has 
polymerized via a multi - photon polymerisation reaction 
creating a bond ( 203 ) to a neighbouring monomer unit ( 201 ) . 
In this embodiment each monomer also comprises a suitably 
designed moiety ( 205 ; represented by a triangle ) , via which 
a second multi - photon process may disassemble the polymer 
when required . [ 0135 ] A composition of the present invention , was pro 
vided including pyrrole as the polymerisable precursor and 
irgacure as the photo - initiator . The composition was injected 
under the skin of a chicken breast . The external surface of 
the chicken breast was illuminated with two laser beams , 
and at the location of intersection , the photo - initiator was 
excited causing localised polymerisation of the pyrrole to 
form polypyrrole . The lasers were used to controllably 
initiate polymerisation in a targeted manner . The polypyrrole 
is shown in FIG . 3 as the dark lines which read “ I heart 
Chemistry ” . 
[ 0136 ] Various modifications and variations of the 
described aspects of the invention will be apparent to those 
skilled in the art without departing from the scope and spirit 
of the invention . Although the invention has been described 
in connection with specific preferred embodiments , it should 
be understood that the invention as claimed should not be 
unduly limited to such specific embodiments . Indeed , vari 
ous modifications of the described modes of carrying out the 
invention which are obvious to those skilled in the relevant 
fields are intended to be within the scope of the following 
claims . 
1 . A method of producing a visual marking on the exterior 
of a human or animal body comprising : 
implanting a composition at a site in the human or animal 
body 1 cm or less from the exterior of the human or 
animal body wherein the composition comprises a 
polymerisable precursor and a photo - initiator wherein 
the photo - initiator causes the polymerisable precursor 
to polymerise where the photo - initiator is in its excited 
state , 
illuminating the site with electromagnetic radiation hav 
ing a wavelength of 400 to 1600 nm , wherein absorp 
tion of two or more photons of the electromagnetic 
radiation excites the photo - initiator causing initiation 
of polymerisation of the polymerisable precursor to 
form a polymer within the human or animal body , 
wherein the polymer is visible on the exterior of the 
human or animal body and wherein the resultant poly 
mer has an electrical conductivity of 10 - 10 S / cm or 
more . 
2 . The method as claimed in claim 1 wherein the resultant 
polymer shows more than one colour on the exterior of the 
human or animal body . 
3 . The method as claimed in claim 1 wherein the visual 
marking is in the form of a tattoo . 
4 . The method as claimed in claim 1 wherein the com 
position is injected into the lower surfaces of the skin of the 
human or animal body and the visual marking may grow out 
as the skin is shed . 
5 . The method as claimed in claim 1 wherein the com 
position is injected under the skin of the human or animal 
body , to provide a permanent visual marking . 
6 . The method as claimed in claim 1 wherein the polymer 
is in the form of a solid , gel , paste or foam ; generally a solid , 
hydrogel or plastics material . 
7 . The method as claimed in claim 1 wherein , the dimen 
sions of the polymer formed ( width , length , thickness ) are at 
least 1 nm , typically at least 100 nm . 
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8 . The method as claimed in claim 1 wherein the two or 
more photons are from intersecting photon beams . 
9 . The method as claimed claim 1 wherein the composi 
tion includes second photo - initiatable functional moieties 
which become excited at a second wavelength different to 
the first wavelength wherein the polymer may be dis 
assembled through illumination of the site with electromag 
netic radiation having the second wavelength , wherein 
absorption of two or more photons of the electromagnetic 
radiation causes the second photo - initiatable functional moi 
eties on the polymer to become excited and dis - assemble the 
polymer . 
10 . The method as claimed in claim 9 wherein the second 
wavelength is at least 200 nm higher or lower than the first 
wavelength . 
11 . The method as claimed in claim 1 wherein the 
composition includes a visual indicator which alters upon 
polymerisation of the polymerisable precursor , wherein the 
visual indicator is visible in the polymerisable precursor but 
not in the polymer , or the visual indicator is visible in the polymer but not the polymerisable precursor . 
12 . The method as claimed in claim 1 wherein the 
composition has a viscosity of from 1 centipoise to 250 , 000 
centipoise . 
13 . The method as claimed in claim 1 , wherein the 
polymerisable precursor comprises , consists or consists 
essentially of monomers having at least one olefinic bond , 
oligomers having at least one olefinic bond , polymers hav 
ing at least one olefinic bond , olefins , halogenated olefins , 
acrylates , methacrylates , pyrroles , acrylamides , bisacrylam 
ides , styrenes , epoxides , cyclohexeneoxide , amino acids , 
peptides , proteins , fatty acids , lipids , nucleotides , oligo 
nucleotides , synthetic nucleotide analogues , nucleic acids , 
sugars , carbohydrates , cytokines , hormones , receptors , 
growth factors , drugs , and mixtures thereof . 
14 . The method as claimed in claim 1 wherein the 
resultant polymer comprises , consists or consists essentially 
of one or more of the group consisting of poly ( fluorene ) s , 
polyphenylenes , polypyrenes , polyazulenes , polynaphtha 
lenes , Poly ( acetylene ) s , Poly ( p - phenylene vinylene ) , poly 
( pyrrole ) s , polycarbazoles , polyindoles , polyazepines , poly ( thiophene ) s , poly ( 3 , 4 - ethylenedioxythiophene ) , poly ( p 
phenylene sulfide ) and polyanilines . 
15 . The method as claimed in claim 1 wherein the 
composition is in the form of a buffered aqueous based 
composition comprising pyrrole , a photo - initiator ( generally 
irgacure ) and a dye . 
